Get the Stockscreener App
4.84
5.10%
-0.26
After Hours:
4.91
0.07
+1.45%
Neogenomics Inc stock is traded at $4.84, with a volume of 4.39M.
It is down -5.10% in the last 24 hours and down -33.79% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$5.10
Open:
$5.11
24h Volume:
4.39M
Relative Volume:
1.79
Market Cap:
$622.88M
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-7.8065
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-24.61%
1M Performance:
-33.79%
6M Performance:
-66.15%
1Y Performance:
-72.70%
1-Day Range:
$4.78
$5.11
1-Week Range:
$4.78
$6.61
52-Week Range:
$4.78
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
4.84 | 658.81M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc.NEO - PR Newswire
Is NeoGenomics Inc. a growth stock or a value stockBest Dividend Picks For 2025 - jammulinksnews.com
What catalysts could drive NeoGenomics Inc. stock higher in 2025AI Powered Growth Plan For 2025 - jammulinksnews.com
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch - MSN
NeoGenomics Earnings Call: Growth Amid Challenges - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionTop Gaining Picks With Entry Signals Identified - metal.it
Analyzing recovery setups for NeoGenomics Inc. investorsLow Drawdown Real Time Trading Tips Shared - metal.it
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower - simplywall.st
Momentum Traders Eye NeoGenomics Inc. for Quick BounceVerified Signal From Chart Patterns Detected - beatles.ru
NeoGenomics (NEO) Meets Q2 Earnings Estimates - MSN
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround - Yahoo Finance
It's Down 27% But NeoGenomics, Inc. (NASDAQ:NEO) Could Be Riskier Than It Looks - 富途牛牛
NeoGenomics launches blood-based cancer profiling test for solid tumors - Investing.com Australia
NeoGenomics launches blood-based cancer profiling test for solid tumors By Investing.com - Investing.com India
NeoGenomics revenue up 10% to USD 181m in Q2 2025 - Medical Buyer
NeoGenomics Targets $5B Market with Revolutionary Blood-Based Cancer Gene Test PanTracer LBx - Stock Titan
NeoGenomics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Neogenomics stock rating downgraded to Neutral by BTIG on execution concerns - Investing.com Canada
Government of Canada partners with United Kingdom to invest in groundbreaking AI alignment research - The Globe and Mail
NeoGenomics Reports Second Quarter 2025 Results - BioSpace
NeoGenomics Inc (NEO) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst Pharma Challenges - Investing.com Canada
Neogenomics 2025 Q2 Earnings Misses Targets as Net Loss Worsens by 141.9% - AInvest
NeoGenomics Reports Revenue Growth Amid Rising Losses - TipRanks
Is NeoGenomics Inc. the Top Chart Pick This WeekLow Risk Equity Screener With Results Shared - metal.it
Neogenomics: William Blair downgrades to 'Market Perform' Rating - AInvest
NeoGenomics Stock Falls 20.2% After Lowered Financial GuidanceNews and Statistics - IndexBox
Neogenomics stock price target lowered to $8 at Needham on weak guidance - Investing.com Canada
Neogenomics Plunges 20.9%—What’s Fueling This Volatility? - AInvest
Why NeoGenomics (NEO) Shares Are Falling Today - Yahoo Finance
NeoGenomics: Q2 Earnings Snapshot - The Washington Post
William Blair downgrades Neogenomics stock rating to Market Perform By Investing.com - Investing.com Canada
Earnings call transcript: NeoGenomics Q2 2025 sees EPS beat, stock drops - Investing.com Australia
NeoGenomics: Navigating Short-Term Pain for Long-Term Gain in Oncology Diagnostics - AInvest
Earnings call transcript: NeoGenomics Q2 2025 sees EPS beat, stock drops By Investing.com - Investing.com South Africa
NeoGenomics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NEO) - Seeking Alpha
Neogenomics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NeoGenomics Q2 2025 slides: Revenue grows 10% but guidance cut sparks selloff By Investing.com - Investing.com South Africa
NeoGenomics shares plunge on slashed revenue guidance - Investing.com
Is NeoGenomics (NEO) a Buy After Missing Q2 Guidance? Assessing Long-Term Growth Potential Amid Short-Term Earnings Disappointments in the Oncology Diagnostics Sector - AInvest
NeoGenomics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Why Did Neogenomics Plunge 15.94% Despite Beating EPS Estimates? - AInvest
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8% - Yahoo Finance
NEOGENOMICS INC SEC 10-Q Report - TradingView
Candlestick Reversal Detected on NeoGenomics Inc.’s ChartHigh Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
NeoGenomics Wants Jury Trial In Natera DNA Test Patent Fight - Law360
What is NeoGenomics Inc. company’s growth strategyBreakout Stocks Tips That Work - jammulinksnews.com
What institutional investors are buying NeoGenomics Inc. stockBreakout Stocks Signals For Fast Growth - jammulinksnews.com
NeoGenomics (NEO): Is This a Buy-the-Dip Opportunity in the Precision Oncology Diagnostics Sector? - AInvest
NeoGenomics Q2 2025 Earnings Preview - MSN
When is NeoGenomics Inc. stock expected to show significant growthGet expert analysis on top stock picks - jammulinksnews.com
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):